BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population
February 22, 2018 at 08:30 AM EST
* CONTRAVIR PHARMACEUTICALS ANNOUNCES TXL™ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:
